SOUTH SAN FRANCISCO, Calif., June 11, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Steve Carchedi has been appointed to the Sunesis Board of Directors, effective immediately.
Currently, Mr. Carchedi serves as the President, Commercial Operations for Mallinckrodt Specialty Pharmaceuticals, the Pharmaceuticals business of Covidien plc. Having held key positions at several leading multinational pharmaceutical companies, Mr. Carchedi brings more than 30 years of commercial industry experience focused in Oncology, Neurology, Urology, Endocrinology and Cardiology. Previously, he served as Chief Marketing Officer for General Electric (GE) Healthcare-MDx where he was responsible for leading worldwide marketing for GE's Medical Diagnostics business. Prior to joining GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson. Mr. Carchedi also held the position of Global Marketing Leader for Johnson & Johnson Oncology, where he led the worldwide product launch of VELCADE® (bortezomib). Before joining Johnson & Johnson, Mr. Carchedi played a key role in commercializing a number of oncology products, including GEMZAR® (gemcitabine) at Eli Lilly & Company, as well as TAXOL® (paclitaxel) and PARAPLATIN® (carboplatin) at Bristol Myers Squibb.
"Steve's extensive experience in oncology drug development and commercialization will be invaluable to Sunesis as we prepare for our future commercial and regulatory milestones," stated Daniel Swisher, Chief Executive Officer of Sunesis. "We welcome Steve to our Board and look forward to his contributions as we advance the VALOR trial to completion and prepare the market for an anticipated launch of vosaroxin in AML.""I am delighted to be joining the talented and dedicated team at Sunesis as a Board member," stated Mr. Carchedi. "Vosaroxin has transformative potential in the AML treatment landscape, and I look forward to sharing my expertise in helping commercialize this exciting oncology candidate and to contributing to the future growth of the company."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts